Evidence map›Paper›PMID 42521716›Full record

ArticleScientific reports2026

A systematic stepwise optimization framework for rapid multi-analyte UPLC-MS/MS plasma analysis with integrated sustainability assessment.

Amira E Abd-Elnabi, Amr M Mahmoud, Dina A El Mously, Omnia A El-Naem

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amira E Abd-ElnabiPostgraduate Program in Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
Amr M MahmoudPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. amr.bekhet@pharma.cu.edu.eg.
Dina A El MouslyPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.
Omnia A El-NaemPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), 6th October City, 11787, Egypt. dr.omniali@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A stepwise optimization guidance model for rapid multi-analyte UPLC-MS/MS is proposed to report recurring limitations in bioanalytical method development. The model involves six stages: (1) physicochemical profiling, (2) extraction strategy selection, (3) chromatographic optimization, (4) mobile phase selection, (5) method validation, and (6) greenness evaluation. The applicability of this framework was demonstrated by determining Rifaximin, Ciprofloxacin, and Fluconazole in spiked human plasma, using Ibuprofen as an internal standard. Physicochemical profiling guided the selection of ionization mode and prediction of solubility behavior. Based on the model recommendations, liquid-liquid extraction using dichloromethane was selected to achieve effective analyte recovery. Chromatographic optimization and mobile phase selection through the proposed framework supported the use of rapid isocratic separation on a C18 column using a methanol/water mixture (95:5, v/v) as mobile phase. The method validation, performed as an integral stage of the workflow according to regulatory guidelines, demonstrated exceptional linearity (r² ≥ 0.999). The final stage of the model involved evaluating environmental applicability using AGSA and EPPI analyses. The proposed sequential framework is intended to serve as a methodological reference for analysts employing LC-MS/MS platforms, to establish a structured and reproducible analytical workflow that advances ecological sustainability in multi-analyte LC-MS/MS bioanalytical applications.

Indexed as

Liquid Chromatography-Mass SpectrometryTandem Mass SpectrometryChromatography, High Pressure LiquidFluconazoleHumansLiquid-Liquid ExtractionReproducibility of ResultsFluconazoleCiprofloxacinFluconazoleRifaximinStepwise optimization guidance modelUPLC–MS/MS

Identifiers

PMID42521716
PMCPMC13415790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.